PMID- 12697735
OWN - NLM
STAT- MEDLINE
DCOM- 20030508
LR  - 20201215
IS  - 0021-9738 (Print)
IS  - 0021-9738 (Linking)
VI  - 111
IP  - 8
DP  - 2003 Apr
TI  - Nonredundant roles of antibody, cytokines, and perforin in the eradication of 
      established Her-2/neu carcinomas.
PG  - 1161-70
AB  - Since the mechanisms by which specific immunity destroys Her-2/neu carcinoma 
      cells are highly undetermined, these were assessed in BALB/c mice vaccinated with 
      plasmids encoding extracellular and transmembrane domains of the protein product 
      (p185(neu)) of the rat Her-2/neu oncogene shot into the skin by gene gun. 
      Vaccinated mice rejected a lethal challenge of TUBO carcinoma cells expressing 
      p185(neu). Depletion of CD4 T cells during immunization abolished the protection, 
      while depletion of CD8 cells during the effector phase halved it, and depletion 
      of polymorphonuclear granulocytes abolished all protection. By contrast, Ig 
      mu-chain gene KO mice, as well as Fcgamma receptor I/III, beta-2 microglobulin, 
      CD1, monocyte chemoattractant protein 1 (MCP1), IFN-gamma, and perforin gene KO 
      mice were protected. Only mice with both IFN-gamma and perforin gene KOs were not 
      protected. Although immunization also cured all BALB/c mice bearing established 
      TUBO carcinomas, it did not cure any of the perforin KO or perforin and IFN-gamma 
      KO mice. Few mice were cured that had knockouts of the gene for Ig mu-chain, 
      Fcgamma receptor I/III, IFN-gamma, or beta-2 microglobulin. Moreover, vaccination 
      cured half of the CD1 and the majority of the MCP1 KO mice. The eradication of 
      established p185(neu) carcinomas involves distinct mechanisms, each endowed with 
      a different curative potential.
FAU - Curcio, Claudia
AU  - Curcio C
AD  - Department of Clinical and Biological Sciences, University of Turin, 10043 
      Orbassano, Italy.
FAU - Di Carlo, Emma
AU  - Di Carlo E
FAU - Clynes, Raphael
AU  - Clynes R
FAU - Smyth, Mark J
AU  - Smyth MJ
FAU - Boggio, Katia
AU  - Boggio K
FAU - Quaglino, Elena
AU  - Quaglino E
FAU - Spadaro, Michela
AU  - Spadaro M
FAU - Colombo, Mario P
AU  - Colombo MP
FAU - Amici, Augusto
AU  - Amici A
FAU - Lollini, Pier-Luigi
AU  - Lollini PL
FAU - Musiani, Piero
AU  - Musiani P
FAU - Forni, Guido
AU  - Forni G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Invest
JT  - The Journal of clinical investigation
JID - 7802877
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Cytokines)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Pore Forming Cytotoxic Proteins)
RN  - 0 (Vaccines, DNA)
RN  - 126465-35-8 (Perforin)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CIN - J Clin Invest. 2003 Apr;111(8):1116-8. PMID: 12697728
MH  - Animals
MH  - Antibodies, Neoplasm/*physiology
MH  - Biolistics
MH  - Cancer Vaccines/*immunology
MH  - Cytokines/*physiology
MH  - Female
MH  - Graft Rejection
MH  - Membrane Glycoproteins/*physiology
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Knockout
MH  - Neoplasm Transplantation
MH  - Neoplasms, Experimental/*therapy
MH  - Perforin
MH  - Pore Forming Cytotoxic Proteins
MH  - Receptor, ErbB-2/*immunology
MH  - Vaccination
MH  - Vaccines, DNA/*immunology
PMC - PMC152940
EDAT- 2003/04/17 05:00
MHDA- 2003/05/09 05:00
PMCR- 2003/04/15
CRDT- 2003/04/17 05:00
PHST- 2003/04/17 05:00 [pubmed]
PHST- 2003/05/09 05:00 [medline]
PHST- 2003/04/17 05:00 [entrez]
PHST- 2003/04/15 00:00 [pmc-release]
AID - 17426 [pii]
AID - 10.1172/JCI17426 [doi]
PST - ppublish
SO  - J Clin Invest. 2003 Apr;111(8):1161-70. doi: 10.1172/JCI17426.